DeLLphi-312 is a Phase 3 clinical trial that is testing an investigational drug called tarlatamab. This clinical trial aims to see how safe and effective tarlatamab is at treating patients with small-cell lung cancer (SCLC). Participants will receive either tarlatamab in combination with durvalumab (Imfinzi®), carboplatin and etoposide, or durvalumab, carboplatin and etoposide alone.
Condition: Small-cell lung cancer (SCLC)
Trial ID: DeLLphi-312
Age: 18+ years old
Phase: 3